Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying users area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Common-Size Income Statement
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Common Stock Valuation Ratios
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get 1-month access to Bristol-Myers Squibb Co. for $19.99, or
get full access to the entire website for at least 3 months from $49.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co. debt to equity ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co. debt to capital ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co. debt to assets ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co. financial leverage ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Debt to Equity
Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Short-term debt obligations | |||||||||||||||||||||||||||||
Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total Bristol-Myers Squibb Company shareholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to equity1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Corp. | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
Debt to equity = Total debt ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co. debt to equity ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Debt to Capital
Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Short-term debt obligations | |||||||||||||||||||||||||||||
Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total Bristol-Myers Squibb Company shareholders’ equity | |||||||||||||||||||||||||||||
Total capital | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to capital1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Corp. | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co. debt to capital ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Debt to Assets
Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Short-term debt obligations | |||||||||||||||||||||||||||||
Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to assets1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Corp. | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co. debt to assets ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Financial Leverage
Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Total Bristol-Myers Squibb Company shareholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Financial leverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||
Cigna Corp. | |||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q2 2022 Calculation
Financial leverage = Total assets ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co. financial leverage ratio increased from Q4 2021 to Q1 2022 but then slightly decreased from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |